Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined as creatinine clearance (CrCl) <50 mL/min...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Haematologica
المؤلفون الرئيسيون:	Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Ferrata Storti Foundation 2023-09-01
الوصول للمادة أونلاين:	https://haematologica.org/article/view/11274

مواد مشابهة

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
حسب: Saurabh Zanwar, وآخرون
منشور في: (2024-06-01)

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
حسب: Hamza Hashmi, وآخرون
منشور في: (2023-10-01)

Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel
حسب: Audrey Couturier, وآخرون
منشور في: (2024-07-01)

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
حسب: Satabdi Saha, وآخرون
منشور في: (2025-07-01)

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
حسب: Bhavesh Mohan Lal, وآخرون
منشور في: (2025-05-01)

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
حسب: Maximilian Merz, وآخرون
منشور في: (2025-01-01)

Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
حسب: Jamie N. Connarn, وآخرون
منشور في: (2023-11-01)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
حسب: Abu-Sayeef Mirza, وآخرون
منشور في: (2023-08-01)

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
حسب: Christopher J. Ferreri, وآخرون
منشور في: (2023-08-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
حسب: Aaron Trando, وآخرون
منشور في: (2024-12-01)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
حسب: Sundar Jagannath, وآخرون
منشور في: (2021-06-01)

Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
حسب: Aimaz Afrough, وآخرون
منشور في: (2024-04-01)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
حسب: Franziska Marquard, وآخرون
منشور في: (2023-11-01)

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
حسب: Djordje Atanackovic, وآخرون
منشور في: (2025-07-01)

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real‐world analysis
حسب: Markus Maulhardt, وآخرون
منشور في: (2025-08-01)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
حسب: Dilara Akhoundova Sanoyan, وآخرون
منشور في: (2023-04-01)

P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C
حسب: Melissa Alsina, وآخرون
منشور في: (2023-08-01)

P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
حسب: Julia Piasecki, وآخرون
منشور في: (2023-08-01)

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
حسب: Krina Patel, وآخرون
منشور في: (2023-08-01)

P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121)
حسب: J. Rytlewski, وآخرون
منشور في: (2022-06-01)

P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
حسب: Salomon Manier, وآخرون
منشور في: (2023-08-01)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
حسب: P Rodríguez-Otero, وآخرون
منشور في: (2022-04-01)

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
حسب: Michel Delforge, وآخرون
منشور في: (2023-08-01)

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
حسب: P. Rodríguez-Otero, وآخرون
منشور في: (2023-05-01)

P1740: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING-ADJUSTED INDIRECT COMPARISON STUDY
حسب: N. Shah, وآخرون
منشور في: (2022-06-01)

P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE
حسب: N. Martin, وآخرون
منشور في: (2022-06-01)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
حسب: Al‐Ola Abdallah, وآخرون
منشور في: (2021-11-01)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
حسب: P Rodríguez-Otero, وآخرون
منشور في: (2022-04-01)

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
حسب: Rahul Banerjee, وآخرون
منشور في: (2025-05-01)

CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective
حسب: Michael Weise, وآخرون
منشور في: (2025-09-01)

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
حسب: Oren Pasvolsky, وآخرون
منشور في: (2025-05-01)

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
حسب: Danai Dima, وآخرون
منشور في: (2025-07-01)

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
حسب: Danai Dima, وآخرون
منشور في: (2025-06-01)

Phenomenological Considerations of Habit: Reason, Knowing and Self-Presence in Habitual Action
حسب: James McGuirk
منشور في: (2016-11-01)

Pasciolla, Francesca (2016). Walt Whitman in Fernando Pessoa. London: Critical, Cultural and Communications Press, pp. 131
حسب: McGuirk, Bernard
منشور في: (2017-12-01)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
حسب: Kellen Gil, وآخرون
منشور في: (2022-05-01)

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
حسب: Sharlene Dong, وآخرون
منشور في: (2025-03-01)

A Model of Directed Graph Cofiber
حسب: Zachary McGuirk, وآخرون
منشور في: (2022-01-01)

Communal sharing within and beyond digital platforms: Prefiguring interdependent sharing cities
حسب: Inka Santala, وآخرون
منشور في: (2022-01-01)

160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy
حسب: Tian Zhang, وآخرون
منشور في: (2023-11-01)